SCHEMBL407626

SCHEMBL407626

CCOC(OCC)C(OCC)(OCC)C(=O)O

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28565059 0.81 LMNA (0.33)
SCHEMBL28468381 0.79
SCHEMBL7470736 0.75
SCHEMBL8411293 0.75
SCHEMBL3989531 0.72 MEN1 (0.32)
SCHEMBL20135785 0.70 THRB (0.35) THRB
SCHEMBL5497973 0.68 CHRM1 (0.30)
SCHEMBL6970379 0.68 MEN1 (0.35) THRB
SCHEMBL27691751 0.67 THRB (0.36) THRB
SCHEMBL9487660 0.67 THRB (0.36) THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1956998-B Method for the purification of albumin conjugates CONJUCHEM INC 2012-12-12 CN disclosed
US-20120022234-A1 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES BOUSQUET-GAGNON NATHALIE (CA) 2012-01-26 US disclosed
EP-2230257-A1 Method for the purification of albumin conjugates ConjuChem Biotechnologies Inc. (CA) 2010-09-22 EP disclosed
EP-2100904-B1 Solid phase for use in a method for the purification of albumin conjugates CONJUCHEM BIOTECHNOLOGIES INC (CA) 2010-07-07 EP disclosed
EP-2100904-A1 Solid phase for use in a method for the purification of albumin conjugates ConjuChem Biotechnologies Inc. (CA) 2009-09-16 EP disclosed
EP-1745078-B1 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES CONJUCHEM BIOTECHNOLOGIES INC (CA) 2009-06-17 EP disclosed
US-20080146783-A1 Method for the purification of albumin conjugates CONJUCHEM BIOTECHNOLOGIES INC. 2008-06-19 US disclosed
US-7307148-B2 Method for purification of albumin conjugates CONJUCHEM BIOTECHNOLOGIES INC. (CA) 2007-12-11 US disclosed
EP-1745078-A4 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES CONJUCHEM BIOTECHNOLOGIES INC (CA) 2007-08-01 EP disclosed
CN-1956998-A Method for the purification of albumin conjugates CONJUCHEM INC (CA) 2007-05-02 CN disclosed
EP-1745078-A1 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES ConjuChem Biotechnologies Inc. (CA) 2007-01-24 EP disclosed
US-20050267293-A1 Method for purification of albumin conjugates CONJUCHEM, INC. (CA) 2005-12-01 US disclosed
WO-2005103087-A1 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES CONJUCHEM BIOTECHNOLOGIES INC. (CA) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022234-A1 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES ALB, DNPEP, SLC7A1 THRB 4127/4885
US-20050267293-A1 Method for purification of albumin conjugates ALB, DNPEP, SLC7A1 THRB 4276/4885
US-20080146783-A1 Method for the purification of albumin conjugates ALB, DNPEP, SLC7A1 THRB 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.